Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment

E-ISSN： 1873-4294|16|19|2179-2188

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.16, Iss.19, 2016-08, pp. : 2179-2188

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

LSD1 inhibition: a therapeutic strategy in cancer?

By Lynch James T Harris William J Somervaille Tim C P

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 12, 2012-12 ,pp. : 1239-1249

Informa Healthcare

Access to resources Recommend Favorite

An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors

Current Medicinal Chemistry, Vol. 24, Iss. 23, 2017-09 ,pp. : 2496-2504

Bentham Science Publishers

Access to resources Recommend Favorite

Irreversible EGFR Inhibitors in the Treatment of Advanced NSCLC

Current Pharmaceutical Design, Vol. 20, Iss. 24, 2014-05 ,pp. : 3894-3900

Bentham Science Publishers

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer

Current Pharmaceutical Design, Vol. 19, Iss. 5, 2013-02 ,pp. : 818-832

Bentham Science Publishers

Access to resources Recommend Favorite

Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer

Current Cancer Drug Targets, Vol. 14, Iss. 9, 2014-11 ,pp. : 775-793

Bentham Science Publishers

Access to resources Recommend Favorite